Xenon Pharmaceuticals Inc's Customers Performance

Name: Xenon Pharmaceuticals Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

XENE

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


XENE's Source of Revenues		• List of XENE Customers

for the same period Xenon Pharmaceuticals Inc

• List of XENE Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Xenon Pharmaceuticals Inc's Comment on Sales, Marketing and Customers

News about Xenon Pharmaceuticals Inc Contracts

Xenon Pharmaceuticals Reports Strong Financial Results and Advances in Epilepsy Program

Xenon Pharmaceuticals Achieves Solid Financial Performance as Its Epilepsy Program AdvancesXenon Pharmaceuticals, a leading biopharmaceutical company, recently released its financial results for the fourth quarter and full year of 2023. The company reported strong growth, driven by its innovative epilepsy program and close collaboration with corporate clients. Additionally, Xenon provided an update on the progress of its Phase 3 epilepsy program, which continues to advance successfully.One of the highlights of Xenon s update was the advancement of its X-TOLE2 and X-TOLE3 trials, focusing on focal onset seizures. These trials have shown promising results thus far, and the company expects to complete patient e...

Xenon Pharmaceuticals to Unveil Exciting Neurology Breakthroughs at AES 2023 Conference

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
VANCOUVER, British Columbia, Dec. 02, 2023 - Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, has recently announced that it will be providing updates on its neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2023). This event provides a significant platform for Xenon Pharmaceuticals to showcase their advancements and achievements in the field of neurology.
Xenon Pharmaceuticals Inc. is dedicated to developing innovative treatments for neurological disorders, including epilepsy. With a focus on preci...

XENE's Stock Performance relative to it's Customers

XENE's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Xenon Pharmaceuticals Inc	5,844.11	13.17	-383.17	370
SUBTOTAL	0.00	0.00	0.00	-

Sources: Xenon Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Xenon Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Xenon Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.